Conference Track

Management of Treatment-Experienced Patients

Source: CCO Independent Conference Coverage of the CCO Independent Conference Coverage of the 2008 ICAAC/IDSA Annual Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Integrase Assay Accurately Determines Raltegravir Susceptibility in Patient Samples With HIV-1 RNA > 500 copies/mL
Enhanced Phenotypic Tropism Assay Accurately, Precisely, and Reproducibly Detects CXCR4-Using Clones at 0.3% of Viral Population
Stable CD4+ Cell Counts Associated With Persistent HIV-1 RNA < 1000 copies/mL
Integrase Resistance Mutations to Raltegravir Associated With Cross-Resistance to Elvitegravir but Not to Second-Generation Integrase Inhibitors
PRO 140 Anti-CCR5 Antibody Safe and Effective in Single-Dose Infusion Study
MOTIVATE: In Post Hoc Analysis, Improved Prediction of Virologic Response With Weighted OBR Drug Susceptibility Scoring vs Standard Susceptibility Scoring
Bevirimat Study 203: Baseline Gag Polymorphisms Associated With Reduced Virologic Response to Bevirimat When Added to Failing HAART
DELPHI: Darunavir/Ritonavir Plus OBR Effective, Well Tolerated in Treatment-Experienced Pediatric Patients
BENCHMRK Studies: Resistance Pathways and Evolution in Patients With Virologic Failure of Raltegravir
ACTG 5211 Reanalysis: Improved Virologic Outcomes When Candidacy for Vicriviroc Therapy Assessed Using Enhanced Phenotypic Tropism Assay
DUET-1 and DUET-2: Etravirine Associated With Reduction in AIDS-Defining Events or Death in Highly Treatment–Experienced Patients
BENCHMRK-1 and -2: Trend Toward Lower Risk for AIDS-Defining Events and Death With Raltegravir vs Placebo in Treatment-Experienced Patients

Expert Analysis

Management of Treatment-Experienced Patients

Faculty:

Eric S. Daar, MD
Joseph J. Eron, Jr., MD
Kimberly Y. Smith, MD, MPH

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss the findings of the reanalysis of ACTG study 5211 using the enhanced phenotypic tropism assay
Explain the impact of assessing antiretroviral activity using a weighted vs standard optimized background regimen susceptibility score
Identify the 3 primary integrase resistance pathways emerging in the BENCHMRK studies of raltegravir
Discuss the risks for AIDS-defining events and death in the DUET and BENCHMRK studies
Summarize recent data on investigational antiretroviral agents

CREDIT INFORMATION

Release Date: December 19, 2008

Expiration Date: December 18, 2009

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 1.1 Nursing contact hours

Pharmacists: 1.1 contact hours (0.11 CEUs)

Status: The activity is not currently available for credit.

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.